Introduction：Basic information about CAS 84449-90-1|Raloxifene, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Raloxifene |
|---|
| CAS Number | 84449-90-1 | Molecular Weight | 473.583 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 728.2±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C28H27NO4S | Melting Point | 250-253°C |
|---|
| MSDS | / | Flash Point | 394.2±32.9 °C |
|---|
Names
| Name | raloxifene |
|---|
| Synonym | More Synonyms |
|---|
Raloxifene BiologicalActivity
| Description | Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>Estrogen Receptor/ERRResearch Areas >>Cancer |
|---|
| Target | Estrogen receptor |
|---|
| In Vivo | Raloxifene (4 mg/kg; intragastrically; daily for 13 weeks) significantly prevents bone loss in ovariectomized (OVX) rats[1]. Animal Model: Female, 12-week-old, Wistar rats (OVX rats)[1] Dosage: 4 mg/kg Administration: Intragastrically; daily for 13 weeks Result: Significantly increased the levels of E2 in OVX rats and significantly decreased the levels of BGP. |
|---|
| References | [1]. Khovidhunkit W, et al. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431-439. [2]. Xu H, et al. Effect of caffeine on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2019;112:108650. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 728.2±60.0 °C at 760 mmHg |
|---|
| Melting Point | 250-253°C |
|---|
| Molecular Formula | C28H27NO4S |
|---|
| Molecular Weight | 473.583 |
|---|
| Flash Point | 394.2±32.9 °C |
|---|
| Exact Mass | 473.166077 |
|---|
| PSA | 98.24000 |
|---|
| LogP | 6.80 |
|---|
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
|---|
| Index of Refraction | 1.666 |
|---|
| InChIKey | GZUITABIAKMVPG-UHFFFAOYSA-N |
|---|
| SMILES | O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12 |
|---|
| Storage condition | Desiccate at +4°C |
|---|
| Water Solubility | DMSO: 28 mg/mL, soluble |
|---|
Safety Information
Synonyms
| [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone |
| Raloxifeno |
| [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone |
| 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidino-ethoxy)benzoyl]benzo[b]thiophene |
| [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone |
| [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(1-piperidinyl)ethoxy]phenyl}methanone |
| [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(piperidin-1-yl)ethoxy]phenyl}methanone |
| UNII-YX9162EO3I |
| Raloxifenum [Latin] |
| Raloxifene [INN:BAN] |
| [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone |
| Raloxifeno [Spanish] |
| Keoxifene |
| [3H]-Raloxifene |
| MFCD00866415 |
| Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]- |
| Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- |
| Raloxifene |
| [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone |
| Raloxifenum |
| [14C]-Raloxifene |
| Raloxifene HCl |
